Biomarker Assay Validation in Healthy Smokers and COPD Smokers and Ex-smokers
NCT ID: NCT02490358
Last Updated: 2016-02-03
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
25 participants
OBSERVATIONAL
2015-06-30
2016-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Sample Collection in Smoking Asthma
NCT01676467
Chronic Obstructive Pulmonary Disease (COPD) Biomarker Identification Study
NCT01780298
Markers for Chronic Obstructive Pulmonary Disease (COPD)
NCT00180622
Endotoxin and Inflammatory Markers in Healthy Non-Smokers and Current Smokers Including Patients With Chronic Obstructive Pulmonary Disease (COPD)
NCT00159289
The MRC/ABPI COPD Cohort v1.7
NCT01620645
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
Healthy smoking subjects
No interventions assigned to this group
2
COPD smoking subjects
No interventions assigned to this group
3
COPD ex-smoker subjects
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Be between 18 and 75 years of age, inclusive, at informed consent.
3. Healthy as determined by a physician, based on medical history and physical examination.
4. Must have smoked regularly in the 12-month period preceding the screening visit and have a pack history of ≥ 5 pack years (number of pack years = number of cigarettes per day/20 x number of years smoked).
1. Must have signed an informed consent indicating that they understand the purpose of and procedures required for the study and are willing to participate in the study.
2. Aged between 40 and 75 years of age inclusive, at the time of signing the informed consent.
3. COPD diagnosis: Subjects with a diagnosis of COPD as defined by the American Thoracic Society (ATS)/European Respiratory Society (ERS) guidelines (Celli, 2004). Symptoms must be compatible with COPD for at least 1 year prior to screening and post-bronchodilator spirometry readings at screening:
* Post-bronchodilator FEV1/FVC ratio of \<0.7
* Post-bronchodilator FEV ≥40 % and ≤80 % of predicted normal values calculated using NHANES reference equations.
Additional Inclusion for Smoking COPD Subjects 1. Must have smoked regularly in the 12-month period preceding the screening visit and have a pack history of ≥ 5 pack years (number of pack years = number of cigarettes per day/20 x number of years smoked).
Exclusion Criteria
2. Positive test for alcohol at screening.
3. Taking prescription medication in the 14 days before screening.
4. Subjects whose primary consumption of tobacco is via methods other than cigarettes (manufactured or self-rolled). Primary methods of tobacco consumption that are excluded include, but are not limited to pipes, cigars and e-cigarettes.
5. Subjects who are unable to produce a total weight of at least 0.1 grams (g) of selected sputum at screening
6. Urinary cotinine levels at screening \< 30 ng/ml.
7. Subject is mentally or legally incapacitated.
8. Subject is an employee of the Sponsor or contract research organization (CRO), or a relative of an employee of the Sponsor or CRO.
9. Any other reason that the Investigator considers makes the subject unsuitable to participate.
1. Upper or lower respiratory tract infection within 4 weeks of the screening visit.
2. Positive test for alcohol at screening.
3. Subjects who are unable to produce a total weight of at least 0.1g of selected sputum at screening.
4. Subject is mentally or legally incapacitated.
5. Subject is an employee of the Sponsor or contract research organization (CRO), or a relative of an employee of the Sponsor or CRO.
6. Any other reason that the Investigator considers makes the subject unsuitable to participate.
7. A history of life-threatening COPD including Intensive Care Unit admission and/or requiring intubation.
8. Taking theophylline in the 28 days before screening
9. Change in COPD medication in the 28 days before screening
10. Taking oral steroids in the 28 days before screening
Additional Exclusion Criterion for Smoking COPD Subjects
1. Subjects whose primary consumption of tobacco is via methods other than cigarettes (manufactured or self-rolled). Primary methods of tobacco consumption that are excluded include, but are not limited to pipes, cigars and e-cigarettes.
2. Urinary cotinine levels at screening \< 30 ng/ml.
Additional Exclusion Criterion for Ex-Smoking COPD Subjects
1\. The subject is a smoker (regular or irregular), or has smoked or used nicotine-containing products within the 6 months prior to screening.
18 Years
75 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Babraham Institute Enterprise Limited
OTHER
Respivert Ltd
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ginny Norris, Dr
Role: STUDY_DIRECTOR
Respivert Ltd
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
London, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ENA003
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.